Optimize your pharmaceutical portfolio strategy
Our pipeline data, historical metrics, deals and milestone information and forecasts arm you with the data you need to optimize your company's portfolio.
As a pharmaceutical company, you need to continually evaluate your disease strategy to discern gaps in your portfolio and decide whether to build or buy. Internal candidates need to be assessed against competitors’ pipelines, and assets suitable for expanding your portfolio identified. To do all this, the right data and analysis is essential.
How we can help
Our portfolio strategy solutions give you timely and accurate intelligence you can act on, including:
Datamonitor Healthcare's expert coverage of key diseases, companies, drugs and market trends makes it the go-to product for pharmaceutical and biotechnology companies to support the development and validation of their strategic plans and commercial decisions.
Key benefits:
Using a peer-reviewed methodology that provides robust, unbiased drug phase success rates and timeline metrics by treatment indication, Pharmapremia enables you to make strong, informed decisions about your drug development pipeline.
Key benefits:
In Vivo
Power your strongest strategy for the year ahead with insights from the Outlook 2021 report. A combination of Scrip’s Scrip 100, Medtech Insight’s Medtech 100, and In Vivo’s Outlook reports, Outlook 2021 is a comprehensive window into the key trends, challenges and opportunities impacting the biopharma, medtech, and generics sectors for the year to come.
Topic Outlook
In Vivo
The COVID-19 pandemic is disrupting global supply chains and companies need effective tools to manage the related contract disputes. Sidley Austin partner Dorothee Schramm and senior associate Katie von der Weid, both specialized in international commercial disputes, provide tips to help companies manage the situation.
In Vivo
In today’s globalized market for medicines, national rules on pricing and access are abundantly shared and more transparent than opaque. In Vivo speaks to the UK branded industry’s negotiator for the latest five-year joint pricing pact with the government, Richard Torbett, who outlines, among other topics, five widely applicable precedents from the talks that can work in “getting to yes” – despite the fractious budgetary climate for health care evident in all major country markets.
Topic Brexit Policy & Regulation
In Vivo
Europe’s patchwork of reimbursement agencies make it a daunting place for a small US biotech to do business. Traditionally large pharma partners or CMSOs have provided an experienced hand to hold, but as a new wave of gene therapies and orphan drugs get the EMA green light, smaller drug developers are applying innovation to commercialization and choosing to go solo.
In Vivo
FDA guidance updated in mid-April offered workarounds for trial sponsors attempting to conduct clinical studies in a time of travel limitations, staffing changes and heightened patient safety issues. For trials involving complex products and administration, such as cell and gene therapies, sponsors must determine whether modified protocols can still maintain trial integrity. If not, it may be time to press pause.
Topic Coronavirus FDA
In Vivo
The idea that public corporations have obligations that extend beyond the fiduciary responsibility to shareholders will be the dominant measure of responsible business behavior in the coming decade. Uncertainty about the extent of these commitments – commonly referenced as the environmental, social and governance (ESG) agenda – has produced equally variable responses from companies in the health care business.
In Vivo
Johan Van Hoof, global head of vaccines at Janssen, talks to In Vivo about the company’s platform, how it is approaching COVID-19 research and the impact of today’s global pandemic on the future of vaccine R&D.
Topic Coronavirus Vaccines
In Vivo
Biomarkers will be key to winning the race to a successful AD drug. Even then, drugmakers must build the infrastructure for getting therapy to the right patients at the right time.
Datamonitor Healthcare, Biomedtracker
The effect of COVID-19 on clinical trials, the industry response, and the return to full operations
Topic Coronavirus Clinical Trials
Citeline, Datamonitor Healthcare
This web event has now ended. You will be able to watch all sessions on demand soon. Register your interest now to receive an update when all sessions are available to view.
Topic Coronavirus
Datamonitor Healthcare
Cardiovascular Diseases (CVDs) are one of the leading causes of disease burden worldwide. This epidemiology overview presents the prevalence of some CVDs and their associated clinical risk factors analyzed by Datamonitor Healthcare.
Topic Cardiovascular
Datamonitor Healthcare
It is important to understand how the biosimilar market has developed over the past five years. Take a look at some of the key events here.
Topic Biosimilars
In Vivo
Bayer’s ambitious campaign to reposition itself as a global leader in two complementary fields – health and nutrition – will face its toughest test in the US, with its highly litigious approach to product liability and a tendency to target pharmaceuticals as the source of the health system’s affordability and access problems.
In Vivo
Immuno-oncology has produced some exciting successes, but the field has become intensely crowded. Enormous resources are being poured into duplicative work and shaky hypotheses—overshadowing other pursuits in cancer research while producing limited results. It is time to re-evaluate how the sector should be pursuing innovation in cancer and how it can be smarter in its use of resources—financial investment, talent, bandwidth, patients and data.
Topic Cancer Research & Development
In Vivo
20 Jan 2021
In Vivo
20 Jan 2021
In Vivo
20 Jan 2021
In Vivo
18 Jan 2021
In Vivo
18 Jan 2021
In Vivo
14 Jan 2021
In Vivo
14 Jan 2021
In Vivo
14 Jan 2021
In Vivo
12 Jan 2021
In Vivo
12 Jan 2021
In Vivo
12 Jan 2021
In Vivo
06 Jan 2021
In Vivo
06 Jan 2021
In Vivo
06 Jan 2021
In Vivo
04 Jan 2021
Getting a demo tailored to your needs is the best way to see how our solutions will help you gain an advantage.
Request live demo now:
Our team is always happy to hear from you. Please call us at:
Have an immediate and specific information need?
Browse and buy from 1000s of analysis and research reports now: